Drug Search Results
More Filters [+]

Zotarolimus

Alternative Names: zotarolimus
Latest Update: 2024-08-13
Latest Update Note: News Article

Product Description

Mechanisms of Action: Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Percutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Colombia

Approved Indications: None

Known Adverse Events: None

Company: Medtronic
Company Location: DUBLIN L2 2
Company CEO: Geoffrey S. Martha
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zotarolimus

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Coronary Artery Disease|Myocardial Infarction|Acute Coronary Syndrome|Angina, Stable|Coronary Restenosis|Myocardial Ischemia|Angina, Unstable|Coronary Stenosis|Angina Pectoris|Inflammation|ST Elevation Myocardial Infarction|Thrombosis|Coronary Disease

Phase 3: Coronary Artery Disease|Arteriosclerosis|Myocardial Ischemia|Coronary Stenosis|Coronary Occlusion

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ONYSOVER

N/A

Recruiting

Myocardial Ischemia|Coronary Artery Disease

2025-12-31

ZEVS-HBR

N/A

Recruiting

Coronary Artery Disease

2024-02-28

DEBORA

N/A

Terminated

Coronary Artery Disease|Myocardial Ischemia

2021-09-29

CNUH-2017-319

N/A

Completed

Myocardial Ischemia|Coronary Artery Disease

2021-03-18

Recent News Events